GR-205171. Antiemetic, tachykinin NK1 antagonist

Drugs of the Future

Volumn 24, Issue 3, 1999, Pages 254-260

  Sorbera, L A ^a   Silvestre, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; ANTIEMETIC AGENT; APREPITANT; EZLOPITANT; LANEPITANT; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NALPITANTIUM CHLORIDE; NKT 343; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW; VOMITING;

EID: 0032907330     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.03.482256     Document Type: Review

References (42)

1. Armour, D.R., Chung, K.M.L., Congreve, M. et al. Tetrazole NK, receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound. Bioorg Med Chem Lett 1996, 6: 1015-20.
2. Armour, D.R., Evans, B., Giblin, G.M.P. et al. (Glaxo Group Ltd.). 3-(5-Tetrazolyl-benzyl)amino-piperidine derivs. and antagonists of tachykinins. EP 720609, US 5703240, US 5843966, WO 9508549.
3. Grélot, L., Miller, A.D. Vomiting: Its ins and outs. News Physiol Sci 1994, 9: 142-6.
4. Chapman, R.W., Hey, J.A., McLeod, R., Minnicozzi, M., Rizzo, C. Tachykinins in the lungs. Drug News Perspect 1998, 11: 480-9.
5. Holzer, P. Tachykinins as targets of gastroenterological pharmacotherapy. Drug News Perspect 1998, 11: 394-401.
6. 1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1 -ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. J Med Chem 1995, 38: 4985-92.
7. 1 receptor antagonist GR203040. Br J Pharmacol 1995, 116: 3158-63.
8. 1 receptor antagonist. Br J Pharmacol 1995, 116: 3149-57.
9. 1 receptor antagonist, GR205171. Br J Pharmacol 1996, 118(Suppl.): Abst 78P.
10. 1 receptor antagonist, on inhaled anesthetics-induced emesis in suncus murinus. Jpn J Pharmacol 1997, 73(Suppl. 1): Abst P377.
11. 1 receptor antagonist. BrJ Pharmacol 1998, 124: 1643-50.
12. 1 receptor antagonist GR205171 prevents vagal stimulation-induced retching but not neuronal transmission from emetic vagal afferents to solitary nucleus neurons in dogs. Brain Res 1998, 802: 221-31.
13. Smith, E.J., Scott, C.M., Bountra, C. The neurokinin 1 (NK) receptor antagonist GR205171 reduces carrageenan-evoked fos-like immunoreactivity in the rat lumbar spinal cord. Br J Pharmacol 1997, 122(Suppl.): Abst 75P.
14. 1 receptor antagonist, GR205171, on apomorphine-induced fos-expression in the rat brainstem. Br J Pharmacol 1998, 123(Suppl.): Abst 223P.
15. 1 receptor antagonist GR205171. Br J Pharmacol 1997, 122(Suppl.): Abst 254P.
16. McAllister, K.H.M., Pratt, J.A. GR205171 blocks apomorphine and amphetamine-induced conditioned taste aversions. Eur J Pharmacol 1998, 353: 141-8.
17. 1 receptor antagonist GR205171 in rats. Neuropharmacology 1998, 37: 1535-43.
18. Abbadie, C., Trafton, J.A., Marchand, S., Wang, H., Mantyh, P.W., Basbaum, A.I. Pharmacological regulation of noxious stimulus-evoked internalization of the neurokinin-1 receptor in the dorsal horn of the rat spinal cord. Soc Neurosci Abst 1997, 23(Part1): Abst 175.15.
19. 1 receptors antagonist, reduces cisplatin-induced nephrotoxicity in the rat. Naunyn-Schmied Arch Pharmacol 1998, 358(1, Suppl. 2): Abst P 41.2.
20. 1 receptor antagonist, in the trigeminovascular system. Regul Pept 1997, 68: 23-9.
21. Goadsby, P.J., Hoskin, K.L., Knight, Y.E. Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 1998, 86: 337-43.
22. 1 receptor antagonist GR205171 in healthy male volunteers. Br J Clin Pharmacol 1998, 46(3): 298P.
23. 1 receptor antagonist GR205171 in patients with chemotherapy-induced or post operative nausea and vomiting. Br J Clin Pharmacol 1998, 46(3): 297P.
24. 1 receptor antagonist, GR205171, in combination with ondansetron. Proc Amer Soc Clin Oncol 1998, 17: Abst 225.
25. 1 receptor antagonist GR205171 in the treatment of PONV following major gynaecological surgery. Anesth Analg 1998, 86(2, Suppl.): Abst S436.
26. 1 receptor antagonist in the acute treatment of migraine. 12th Migraine Trust Int Symp (Sept 1-4, London) 1998, Abst 9.2.
27. GR-205171 development status. Glaxo Wellcome plc Company Communication Jan 28, 1999.
28. Hale, J.J., Mills, S.G., MacCoss, M. et al. Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3(S)-(4-fluoro)phenyl-4-(3- oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998, 41: 4607-14.
29. 1 receptor. J Pharmacol Exp Ther 1996, 277: 900-8.
30. Sarau, H.M., Griswold, D.E., Potts, W. et al. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 1997, 281: 1303-11.
31. Aramori, I., Morikawa, N., Zenkoh, J., O'Donnell, N., Iwami, M., Kojo, H., Notsu, Y., Okuhara, M., Ono, S., Nakanishi, S. Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors. Eur J Pharmacol Mol Pharmacol Sect 1994, 269: 277-81.
32. 1 receptor antagonist. Br J Pharmacol 1998, 124: 83-94.
33. 1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523. Eur J Pharmacol 1996, 310: 37-46.
34. Kudlacz, E.M., Shatzer, S.A., Knippenberg, R.W., Logan, D.E., Poirot, M., van Giersbergen, P.L., Burkholder, T.P. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist. J Pharmacol Exp Ther 1996, 277: 840-51.
35. Cascieri, M.A., Macleod, A.M., Underwood, D. et al. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem 1994, 269: 6587-91.
36. Gitter, B.D., Bruns, R.F., Howbert, J.J. Pharmacological characterization of LY303870: A novel, potent and selective non-peptide substance P (neurokinin-1) receptor antagonist. J Pharmacol Exp Ther 1995, 275: 737-44.
37. 1 receptor antagonist. Eur J Pharmacol 1993, 250: 403-13.
38. 1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J Med Chem 1998, 41: 3159-73.
39. 1 receptor antagonist, in ferrets. Eur J Pharmacol 1996, 305: 181-5.
40. 1 receptor antagonists in ferrets by their ability to inhibit GR73632-induced foot tapping in gerbils. Br J Pharmacol 1997, 120(Suppl.): Abst 363P.
41. 1 antagonists. J Med Chem 1996, 39: 2907-14.
42. Hale, J.J. et al. Synthesis and biological characterization of long-acting, orally active morpholine acetal human NK-1 receptor antagonists. 213th ACS Natl Meet (April 13-17, San Francisco) 1997, Abst MEDI 060.